# Rigetti Computing, Inc. (RGTI) — InvestMoat Analysis

_Last analyzed: July 16, 2026_
_Asset class: equity · Canonical page: https://investmoat.com/stocks/rgti_

## Scores

| Dimension | Score (0–100) |
| --- | --- |
| Moat durability | 48 |
| Growth trajectory | 64 |
| Valuation | 60 |
| **Composite** | **56** |
| **Recommendation** | **Avoid** |

Scores are computed deterministically from this asset’s data by the InvestMoat formula (see https://investmoat.com/llms.txt for methodology). Scores are not directly comparable across asset classes.

## Key stats

- **Ticker:** RGTI (Nasdaq)
- **Market Cap:** ~$5.4B

## Moat

A narrow, unproven moat from full-stack superconducting expertise, an in-house chip fab, scarce quantum talent, and government relationships — a genuine technical franchise, but one a clear step behind IonQ on fidelity, with revenue that actually shrank in 2025.

### The Full-Stack Superconductor

Rigetti's durability is engineering-, fab-, and talent-based — not yet commercial. **Three** early-stage pillars, all behind the frontier:

- **Vertically Integrated Fab & Stack:** Rigetti operates its own superconducting-chip foundry (Fab-1) and a full stack from chip design to the Rigetti QCS cloud and the Novera on-prem QPU. Owning fabrication lets it iterate its multi-chiplet architecture faster than fabless rivals — a real differentiator, but capital-intensive and still producing only single-digit-millions of revenue.
- **Scarce Superconducting Talent:** Rigetti is one of a handful of teams that can design, fabricate, and operate superconducting quantum processors at cadence. This expertise is among the scarcest in the economy and AI-resilient — AI augments but cannot replace it — though it is execution capability, not a structural lock-in, and the team is smaller and less capitalised than IonQ's.
- **Government & Ecosystem Ties:** An AFRL quantum-networking contract, Innovate UK QEC funding, NVIDIA's NVQLink integration, and a US Dept. of Commerce CHIPS Act LOI (up to $100M) give Rigetti scarce government pedigree and cloud reach (Amazon Braket). But it was not initially selected for DARPA QBI Stage B, and its franchise is nascent versus larger, better-funded competitors.

**Moat verdict:** Rigetti's applicable moats — full-stack superconducting engineering, an in-house fab, scarce talent, and government ties — are AI-resilient because AI cannot replicate the underlying hardware physics or fabrication know-how. It carries none of the AI-vulnerable software moats (no learned interface, business-logic, data, transaction, or system-of-record lock-in), so AI cannot erode what durability it has. The blunt limitation is that the moat is narrow and unproven, and unlike IonQ the near-term evidence is negative: revenue shrank in 2025, most moat categories are N/A or weakened, and a ~$5.4B market cap rests almost entirely on a scaling roadmap that has yet to convert into a real business. A credible superconducting effort, but a speculative, second-tier bet within an already-speculative group.

## Growth

Rigetti is the hardest of the quantum pure-plays to underwrite on growth: FY2025 revenue actually declined to $7.1M (from $10.8M), Q4 2025 was just $1.9M, and management issued no firm 2026 revenue guidance. The recovery case rests on specific, lumpy hardware orders — a $5.7M Novera on-prem system and an $8.4M C-DAC 108-qubit deployment — plus a technical roadmap (>150 qubits at 99.7% fidelity by late 2026, >1,000 by end-2027). The company is well-funded (~$569M, no debt) against a low ~$16M quarterly burn, so survival is not the question; the question is whether tiny, project-based revenue can ever compound into a real commercial business, and on that the near-term trajectory has been negative, not positive.

- **Revenue CAGR estimate:** 15–25%
- **Primary type:** both
- **Margin trend:** compressing
- **Key risk (severe):** Rigetti's revenue declined in 2025 and remains a handful of lumpy hardware deals, yet the stock carries a ~$5.4B market cap (~750× trailing sales). If chiplet scaling slips, if the >1,000-qubit 2027 roadmap misses, or if orders fail to convert into recurring revenue, the valuation has no fundamental support and the stock de-rates sharply toward its ~$569M cash value.
- **Drivers:**
  - Hardware Orders & Backlog — $5.7M Novera on-prem + $8.4M C-DAC (India) 108-qubit system (H2 2026) — the near-term revenue bridge after a down 2025 (accelerating)
  - QCS Cloud & Amazon Braket Access — Cepheus-1-108Q generally available; recurring but small quantum-compute-as-a-service revenue (stable)
  - Reported Revenue Base — FY2025 revenue fell to $7.1M from $10.8M; Q4 2025 just $1.9M — the trailing trend was negative (decelerating)
- **Score derivation:** Base 83 (~20% assumed 3–5yr CAGR off a tiny base, 15–30% band) + 0 trajectory (order backlog accelerating but 2025 revenue actually declined) − 4 margin (persistent operating losses, no margin leverage at this scale) + 4 both (chiplet-scaling TAM plus system-sale share) − 15 severe risk (revenue shrank in 2025; growth is order-dependent and unproven) = 68.

## Valuation

At ~$16.25 (~$5.4B) Rigetti trades at roughly 750× trailing sales against declining revenue and persistent operating losses — arguably the richest valuation-to-fundamentals ratio of the quantum pure-plays. The price sits above our $12 base case and about a quarter of the way into the $30 bull case, near the average analyst target of ~$29–30 but with essentially no margin of safety. The ~$569M net cash (~$1.70/share) is a genuine floor but a small fraction of the market cap; almost the entire value is a bet on the superconducting roadmap converting into commercial revenue it has not yet demonstrated.

**Fair value:** $12 (base) — well below the current price; unsupported by fundamentals, with upside entirely roadmap-contingent — P/E is omitted — Rigetti is deeply loss-making (Q1 2026 operating loss $(26.0)M; the +$33.1M GAAP net income is a non-cash warrant gain) with no profitability in sight. Valuation rests entirely on price/sales (~750× trailing) and roadmap credibility, and revenue actually declined in 2025 — so even the sales-multiple denominator is shrinking. The premium is paid for the fab, the talent, and >1,000-qubit optionality, not any current business.

## Price scenarios

### Bear — $6

The market stops paying 750× sales for a shrinking-revenue quantum name: milestones slip, orders stay lumpy, and the stock re-rates toward its cash value as speculative capital exits.

- The >150-qubit (late 2026) or >1,000-qubit (2027) chiplet milestones slip, undercutting the scaling thesis
- Revenue stays flat-to-down as hardware orders fail to convert into recurring QCaaS revenue
- A 'quantum winter' compresses the multiple toward cash value (~$1.70/share), amplified by continued ATM and CHIPS-related dilution

### Base — $12

Rigetti delivers the near-term orders (Novera, C-DAC) and roughly hits its late-2026 fidelity milestone, but revenue stays small and the market pays a cooling-but-still-speculative multiple, leaving the stock range-bound below its highs.

- The $5.7M Novera and $8.4M C-DAC orders convert on schedule, returning revenue to modest year-on-year growth
- Cepheus-class systems reach >150 qubits at ~99.7% fidelity by late 2026, keeping Rigetti technically credible
- Forward price/sales compresses as the market waits for the >1,000-qubit 2027 milestone to prove the scaling curve

### Bull — $30

The chiplet flywheel inflects: Rigetti hits >1,000 qubits with improving fidelity, orders accelerate into recurring revenue, and the market re-rates it as a credible superconducting scaler alongside the mega-cap efforts.

- The multi-chiplet architecture reaches >1,000 qubits near the end-2027 target with error rates halving on schedule
- Government funding (CHIPS Act LOI, AFRL) and NVIDIA NVQLink integration convert into a durable, growing contract book
- Operating losses narrow as system sales and QCaaS scale, letting the market underwrite a platform premium rather than pure optionality

---

InvestMoat is an open-source research and education framework. Nothing here is financial advice. Past performance does not guarantee future results.
